2-Hydroxy nevirapine-d3
2-Hydroxy nevirapine-d3 (2-OH NVP-d3) is the deuterated-labeled 2-Hydroxy nevirapine (2-OH NVP) (HY-W739986). 2-Hydroxy nevirapine (2-OH NVP) is a phase I metabolite of Nevirapine (HY-10570) and an Aryl Hydrocarbon Receptor activator. It induces hepatic Apolipoprotein A1 levels and modulates paraoxonase-1 enzyme activity. 2-Hydroxy nevirapine is used in research on atherosclerosis and HIV-1 infection.
For research use only. We do not sell to patients.
- CAS No.: 1329834-05-0
- Formula: C15H11D3N4O2
- Molecular Weight:285.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1329834-05-0
-
Unlabeled CAS 254889-31-1
-
Molecular Weight 285.32
-
Formula C15H11D3N4O2
-
SMILES
[2H]C([2H])(C1=CC(O)=NC2=C1NC(C3=CC=CN=C3N2C4CC4)=O)[2H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- 2-Hydroxy nevirapine-d3
- 1329834-05-0
- Isotope-Labeled Compounds
- Drug Metabolite
- Aryl Hydrocarbon Receptor
- aryl hydrocarbon receptor activator
- HepG2 cell monolayer cultures
- IgG anti-HDL antibodies
- 2D primary cultures of rat hepatocytes
- CYP1A1/1A2
- 3D primary rat hepatocyte spheroid cultures
- atherosclerosis
- paraoxonase-1
- hepatic apolipoprotein A1
- HIV-1 infection
- Inhibitor
- inhibitor
- inhibit